ArticleNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2022

Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.

Michael Benatar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.